A Cochrane meta-analysis of 22 studies with nearly 2,000 participants found intermittent fasting is not particularly effective for weight loss in obese or overweight adults and does not differ significantly from standard dietary advice. Experts note it remains an alternative at least as effective as classic calorie restriction, but more long-term trials are needed.
A Cochrane review found intermittent fasting did not beat standard diet advice for weight loss. A separate trial found it matched calorie restriction but felt less restrictive. Experts advise a case-by-case approach given limited evidence.
A Cochrane review of 17 trials finds amyloid-beta-targeted monoclonal antibodies offer negligible benefit in MCI or mild Alzheimer’s. In a phase 3 trial, the oral agent valiltramiprosate (ALZ-801) showed significant cognitive and functional improvements in the MCI subgroup, with no brain swelling risk. The company plans another phase 3 study in 2026.
A new Cochrane review said anti-amyloid Alzheimer’s drugs show no clinically meaningful benefit, but many researchers said the analysis has major limitations. Newer evidence on lecanemab and donanemab and broader drug development efforts continue to shape the field.
A new Cochrane review analyzing 22 randomized clinical trials involving 1,995 adults found intermittent fasting produces no clinically meaningful weight loss compared to traditional dietary advice or no intervention.
Daily aspirin use does not prevent bowel cancer in the general population within 5-15 years and carries immediate bleeding risks, according to a new Cochrane review. However, long-term low-dose aspirin is associated with lower colorectal cancer risk in IBD patients.
A new Cochrane review of 22 randomized trials finds intermittent fasting produces little to no meaningful weight loss compared to traditional dietary advice or no intervention in overweight or obese adults.
